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Abstract
Background: The a2-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under
ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro
model for traumatic brain injury.
Methods: Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed
to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In
addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway
inhibitors were examined.
Results: Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum
effect at a dosage of 1 μM. This effect was partially reversed by the simultaneous administration of the ERK
inhibitor PD98059.
Conclusion: In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that
activation of ERK might be involved in mediating this effect.
Keywords: Neuroprotection, Traumatic brain injury, Dexmedetomidine
Background
In the United States an estimated 1.1 million patients
are treated for traumatic brain injury (TBI) annually [1].
Of these, 124.000 patients suffer from long-term disabil-
ities and 50.000 die, which makes TBI a major cause of
premature death [1,2]. In addition, long term medical
care and loss of income create a considerable social and
economical burden, which remains an unsolved public
health problem [3]. Regrettably, to date there exists no
clinically established therapy targeting the mechanisms
involved in TBI and treatment remains limited to symp-
tomatic approaches.
Dexmedetomidine is a highly selective a2-adrenorecep-
tor agonist with sedative, analgesic and sympatholytic
properties. It was developed and investigated during the
1980s and 1990s and was initially used to achieve seda-
tion and analgesia in veterinary medicine. In 1999 it was
approved for use in humans by the US Food and Drug
Administration for short-term sedation (< 24 h) of
patients in intensive care units and non-intubated
patients prior to and during surgical procedures.
Recently, dexmedetomidine was approved in Europe for
sedation of adult intensive care unit patients requiring a
sedation level not deeper than arousal in response to
verbal stimulation.
Besides dexmedetomidine’s well-proven sedative effects
an increasing body of both in vitro and in vivo evidence
indicates that dexmedetomidine also exerts a cell-protec-
tive effect on nervous tissue under ischemic conditions
[4-7]. There is recent evidence suggesting that this effect is
mediated not only by dexmedetomidine’s a2-agonistic
properties, but also by the binding to imidazoline I1-rece-
pors [8]. The signal transduction cascade linked to these
receptors comprises extracellular signal-regulated protein
kinase 1 and 2 (ERK 1&2) and is known to be an impor-
tant regulator for cell survival and mediator of neuropro-
tective effects of various agents [9-11]. Nevertheless it has
yet to be determined whether dexmedetomidine also
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promotes survival of nervous tissue that has suffered trau-
matic injury.
In this study we tested the hypothesis that dexmedeto-
midine has a protective effect on traumatically injured
brain tissue as well. We used organotypic hippocampal
brain-slice cultures subjected to a focal mechanical
trauma as an in vitro model of TBI to analyse a poten-
tial neuroprotective effect of dexmedetomidine in TBI.
Methods
All experiments in the course of this study were approved
by the animal protection representative at the Institute of
Animal Research at RWTH Aachen University Hospital,
according to the German animal protection law §4, Sec-
tion 3. Unless otherwise stated all chemicals were obtained
from PAA Laboratories GmbH (Pasching, Austria).
Hippocampal slice culture
The organotypic hippocampal slice cultures were prepared
from brains of 5-7 day old C57/BL6 mice pups using a
well-established technique [12-14]. After decapitation of
the pups the brains were quickly extracted from the sculls
and placed into ice cold preparation medium comprising
Gey’s balanced salt solution (Sigma Aldrich, Steinheim,
Germany), 5 mg/ml D-(+)-glucose (Roth, Karlsruhe,
Germany) and 0.1% antibiotic/antimycotic solution (con-
taining penicillin G 10,000 U/ml, streptomycin sulphate
10 mg/ml and amphotericin B 25 μg/ml).
The hippocampi were then dissected from the brains
under stereomicroscopic vision, cut into 400 μm thick
slices and dispersed onto the semi-permeable membrane
of MilliCell tissue culture inserts (MilliCell-CM, Millipore
Corporation, Billerica, MA, USA). These inserts were
placed inside 35 mm tissue culture plates (Sarstedt,
Newton, MA, USA) and 1 ml of growth medium (50%
Eagle minimal essential medium with Earle’s salts, 25%
Hank’s balanced salt solution (Sigma-Aldrich, Steinheim,
Germany), 25% heat inactivated horse serum, 2 mM L-glu-
tamine, 5 mg/ml D-glucose, 1% antibiotic/antimycotic
solution and 50 mM HEPES (hydroxyethyl-piperazine-
ethanesulfonic acid) buffer solution (Sigma-Aldrich,
Munich, Germany), titrated to pH 7.2) was instilled under
the membranes to ensure optimal nutrition of the slices.
The slices were then incubated for 14 days at 37°C and a
moist atmosphere of 95% air and 5% CO2. The growth
medium was replaced 24 h after preparation and on every
third day thereafter.
Traumatic brain injury protocol
On the day of the experiment growth medium was
exchanged for experimental medium containing 4.5 μM
propidium Iodide. Experimental medium differed from
growth medium only in the substitution of horse serum
for more Eagle minimal essential medium assuring a
standardized experimental environment for all slices. The
slices were then incubated for 30 min at 37°C with a moist
atmosphere of 95% air and 5% CO2 before capturing base-
line fluorescence images. Slices were then traumatized
using a specially designed apparatus that ensured an equal
and reproducible trauma during the course of the experi-
ments [15,16]. For this purpose a metal stylus was lifted 7
mm above the slice with the aid of an electromagnet.
When power to the magnet was switched off the stylus fell
onto the slices producing a mechanical trauma of 5.26 μJ
onto the hippocampus’s CA1 region. The stylus was
retrieved immediately after the impact and experimental
medium was exchanged for new experimental medium in
those plates belonging to the positive control group. In the
experimental groups dexmedetomidine (Precedex® 100
μg/ml Dexmedetomidine, Orion Pharma, Espoo, Finland)
was added to this experimental medium in various con-
centrations (100 μM, 10 μM, 5 μM, 1 μM, 0.1 μM, 0.01
μM). Concentrations were prepared based upon a molar
weight of 236.7 g/mol for dexmedetomidine-HCl as a
basis. For the negative control group (non-traumatized
slices), data from a previous, methodically identical study
was used [12].
To further investigate the protective properties of
dexmedetomidine, a series of other experiments was
performed using a 1 μM concentration which in the
dose-finding study had been proven to be the most
effective dose. To assess possible neuroprotective effects
in a delayed application, experiments were repeated for
1 μM dexmedetomidine, exchanging experimental med-
ium at 2 and 3 h after the trauma, respectively. In order
to verify the hypothesis that dexmedetomidine’s neuro-
protective properties involve activation of ERK the mito-
gen-activated/extracellular signal-regulated protein
kinase kinase 1 (MEK1) -inhibitor PD98059 (Cell Signal-
ing Technology, Danvers, MA, USA) was added in a
5 μM concentration to the experimental medium con-
taining 1 μM dexmedetomidine.
All slices were incubated for 72 h at 37°C and a moist
atmosphere of 95% air and 5% CO2 after trauma.
In order to compare the effects of dexmedetomidine
on cell survival with those of hypothermia, a positive
control group of slices was incubated at 32° and a moist
atmosphere of 95% air and 5% CO2 for 72 h after
trauma. An experimental group exposed to 1 μM of
Dexmedetomidine was also incubated at 32°C for 72 h
after trauma to study a possible synergistic effect of dex-
medetomidine and hypothermia.
Quantification of cell death and statistical analysis
After the incubation period final fluorescence images
were taken.
To quantify cell death propidium iodide was present
in the media throughout all experiments. Propidium
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iodide is a widely used dyeing agent able to bind to
nuclear DNA in a non-specific manner. Upon binding it
becomes highly fluorescent with a peak emission in the
spectrum of visible red light. Its properties render it
incapable of penetrating intact phospholipids bilayers
such as the cell membrane and the nuclear membrane.
However, if the integrity of the cellular membranes is
disrupted as in apoptotic or necrotic processes, propi-
dium iodide can diffuse into the nucleus and stain the
DNA.
Baseline and final fluorescence images were taken
using an upright fluorescence microscope (Zeiss Axio-
plan, Carl Zeiss MicroImaging GmbH, Jena, Germany)
equipped with a rhodamine filter and a low-power x4
objective lens (Zeiss Achroplan 4x/0.10, Carl Zeiss
MicroImaging GmbH, Jena, Germany) and captured
with a digital camera (SPOT Pursuit 4 MP Slider, Diag-
nostic Instruments Inc, Sterling Heights, MI, USA) and
applicable software.
To eliminate any influence of the mercury lamp’s fluc-
tuating intensity, the exposure time was adapted before
each imaging session using a standard fluorescence slice
(Fluor-Ref, Omega Optical, Brattleboro, VT, USA) as
reference.
ImageJ software was used to analyze the images. The
fluorescence intensity of each pixel of the red channel
was broken down to an eight bit value (between 0 and
255). Areas with high fluorescence values were equiva-
lent to high propidium iodide uptake, thus strong cell
damage. A histogram was then created showing the dis-
tribution of intensities within the image. Results of pre-
viously conducted studies using the same method
[12,13,17] point out that values below a threshold of
100 represent background fluorescence. Therefore, only
values beyond this threshold were summarized and this
integral served as a quantitative measure for cell death
(Figure 1).
Statistical analysis
Mean ± SEM (standard error of the mean) was calcu-
lated for each group using SPSS 19 (IBM® SPSS® Statis-
tics, IBM Corporation, Somers, NY, USA). The
fluorescence value of the positive control group was set
to unity (1 ± 0.037) and served as a reference to put the
observed effect of dexmedetomidine on cell survival into
perspective. Values of all other groups were normalized
to the positive-control group. Statistical relevance of the
results was assessed performing an analysis of variance
Figure 1 Control Data. Slices were cultivated for 14 days before being subjected to TBI introduced by a stylus dropped onto the CA1 region.
Slices were then incubated in an atmosphere of 95% air and 5% CO2. Negative control group slices were treated the same way, except for the
trauma. After 72 h trauma intensity was assessed by fluorescence imaging and pixel based analysis. The fluorescence intensity corresponded to
the trauma intensity of each pixel and was broken down to a value between 0 and 255. The histogram shows the distribution of pixels for the
different fluorescence intensities for the negative control group (n = 35, labelled a) and the slices of the positive control group (n = 185, labelled
b). The middle line represents the mean for each fluorescence value; the upper and lower lines represent the upper and lower boundaries of the
SEM. The interrupted vertical line is the applied threshold at a grey scale value of 100. The sum of all pixels beyond this threshold was calculated
for each group and served as a measure for trauma intensity. Above the graph, example images for the negative control group (left) and
positive control group (right) are shown. The insert in the upper right corner represents the trauma levels of both control groups normalized to
the positive control group.
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(ANOVA). P ≤ 0.05 was considered statistically
significant.
Results
As Figure 2 points out the concentrations 10 μM, 5 μM,
1 μM and 0.1 μM showed a significant reduction in
trauma intensity with a maximum effect at 1 μM, where
the fluorescent value was 42.9% of the positive control
group’s value. No significant change in trauma intensity
was observed at 100 μM (1.094 ± 0.065 vs. 1 ± 0.037,
P = 0.213) and 0.01 μM (0.949 ± 0.061 vs. 1 ± 0.037,
P = 0.485).
While hypothermia proved to be neuroprotective when
comparing its effects to the positive control group (0.659
± 0.074 vs. 1 ± 0.037, P < 0.001), hypothermia was asso-
ciated with significantly less neuroprotection than dex-
medetomidine at a concentration of 1 μM (0.659 ± 0.074
vs. 0.429 ± 0.046, P = 0.008). The simultaneous applica-
tion of hypothermia and 1 μM dexmedetomidine was
neither significantly superior nor inferior to the applica-
tion of 1 μM dexmedetomidine alone (0.578 ± 0.064 vs.
0.429 ± 0.046, P = 0.073) (Figure 3).
Also, the delayed application of dexmedetomidine (2 h
and 3 h after trauma, respectively) showed a protective
effect. Application of dexmedetomidine 2 h after trauma
proved even more efficient than immediate application
(0.27 ± 0.028 vs. 0.429 ± 0.046, P = 0.030) while a delay
of three hours (0.363 ± 0.04 vs. 0.429 ± 0.046, P =
0.335) resulted in similar effects as the instantaneous
application (Figure 4).
The simultaneous application of 1 μM dexmedetomi-
dine and PD98059 resulted in a statistically significant
reduction of cellular protection (0.578 ± 0.051 vs. 0.429 ±
0.046, P = 0.033) (Figure 5).
Discussion
The aim of this study was to investigate the effects of the
a2-adrenoreceptor agonist dexmedetomidine on cell sur-
vival in an established in vitro model for TBI. Using orga-
notypic hippocampal slice cultures subjected to a focal
mechanical trauma we found that dexmedetomidine had
a dose-dependent protective effect on hippocampal cells.
The dose-effect curve was U-shaped, with a concentra-
tion of 1 μM showing the strongest effect. Moreover, we
observed neuroprotection by dexmedetomidine even
when applied with a delay after the onset of the traumatic
injury. Apparently, the neuroprotective effects of
Figure 2 Neuroprotective effect of dexmedetomidine. After
trauma, slices were exposed to varying concentrations of
dexmedetomidine. Following 72 h of incubation fluorescence
images were taken and analysed. For each group an average of 52
slices with a minimum of 39 slices was used. Trauma intensities of
the different groups are shown in relation to trauma intensity in the
positive control group (n = 185). Trauma intensity was significantly
lower in the groups 10 μM, 5 μM, 1 μM and 0.1 μM (*p ≤ 0.05, **p
≤ 0.001) when compared to the positive control group. In contrast,
the groups 100 μM and 0.01 μM showed no statistical difference
compared to the positive control group (p = 0.213 and p = 0.485,
respectively).
Figure 3 Hypothermia. We subjected a group of slices (n = 49) to
mild hypothermia of 32°C for 72 h after TBI to distinguish the
observed dexmedetomidine protection from already determined
neuroprotective treatment. Furthermore, we treated another group
of slices (n = 68) simultaneously with both mild hypothermia and 1
μM dexmedetomidine to investigate a potential additive effect of
both treatments. Figure 3 shows that treatment with mild
hypothermia caused a significant reduction of trauma intensity
when compared to the positive control group (p ≤ 0.001). However,
this protective effect was significantly lower than protection
provided by 1 μM dexmedetomidine (p = 0.008). Treatment with
both hypothermia and 1 μM dexmedetomidine proved to be more
effective in reducing trauma than hypothermia alone (p = 0.415)
but showed no statistical difference compared to a treatment with
1 μM dexmedetomidine alone (p = 0.073).
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dexmedetomidine are mediated - at least in part - by ERK
as they were abolished by the co-administration of
PD98059. Interestingly, the co-application of hypother-
mia and dexmedetomidine did not exert synergistic
effects.
We treated experimental groups with varying concentra-
tions of dexmedetomidine after trauma. Results show that
a concentration of 1 μM dexmedetomidine was most
effective at reducing trauma intensity. This finding is con-
sistent with data from a recent study using hippocampal
slice culture subjected to oxygen and glucose deprivation
[5]. Further dilution as well as a higher concentration of
dexmedetomidine provided lower protection until finally,
at 100 μM and 0.01 μM, no difference compared to the
positive control group was observed. Comparable observa-
tions have been made in other studies investigating dex-
medetomidine’s protective properties [5,18].
Dexmedetomidine’s neuroprotective properties have lar-
gely been attributed to its agonist actions at a2-adrenore-
ceptors [19,20]. Although recent investigations point out
that its interaction with imidazoline I1 receptors and the
activation of ERK might also play a role [5,8,21] we did
not explicitly analyze imidazoline I1 receptors. However,
the results of our experiments indicate that activation of
ERK is an important factor in the protection of trauma-
tized nervous tissue by dexmedetomidine. ERK is a key
enzyme in cell metabolism activated by many different
types of tissue injury and has been attributed a “survival”-
function. The inhibition of a survival signals itself can
cause cells to undergo apoptosis; therefore application of
PD98059, inhibitor of ERK’s direct activator MEK1, might
as well have had a negative effect on cellular survival that
superposed with the positive effect of dexmedetomidine
without specifically counteracting dexmedetomidine. To
rule out this possibility western blots could have been per-
formed. Comparison of levels of activated ERK for the
positive control group, the 1 μM dexmedetomidine group
and the 1 μM dexmedetomidine + PD98059 group could
have backed up our hypothesis. This has recently been
performed in a similarly designed study investigating
dexmedetomidine’s neuroprotective properties using orga-
notypic hippocampal slice cultures subjected to oxygen
and glucose deprivation. Results of this study showed that
dexmedetomidine’s and PD98059’s effects do not simply
superpose but that both act as two opponents on the same
cascade [5]. We therefore decided not to perform these
tests and interpreted our finding as a sufficient hint
towards an involvement of ERK in the mediation of the
brain protective properties of dexmedetomidine in TBI.
Many experimental studies have revealed neuroprotec-
tive properties of hypothermia [13,16,22,23] and the
advantages of hypothermia in certain clinical circum-
stances have been demonstrated [24]. To put our findings
into context we subjected a group of slices to mild
Figure 4 Delayed application of dexmedetomidine. Here, we
applied dexmedetomidine 2 and 3 h after TBI in a concentration of
1 μM. The two-hour delay group contained n = 24 slices and the
three-hour delay group contained n = 31 slices. We found that both
groups showed a level of trauma intensity significantly lower than
the positive control group’s (p ≤ 0.001). An application delayed by 2
h appeared to protect slices even better than immediate application
of dexmedetomidine (p ≤ 0.05). After a delay of 3 h no statistical
difference from an immediate application was observed (p = 0.335).
Figure 5 MEK-Inhibitor. To investigate whether the ERK1/2-
pathway is involved in the mediation of dexmedetomidine’s
neuroprotective properties towards mechanically injured brain tissue
we applied PD98059, inhibitor of ERK1/2’s direct activator MEK1, in a
5 μM concentration along with 1 μM dexmedetomidine
immediately after trauma. Here, n = 46 slices were subjected to the
aforementioned conditions. As shown in Figure 5 trauma intensity
was significantly higher in the inhibitor group than in the
dexmedetomidine group (p = 0.033) but still appreciably lower than
in the positive control group (p ≤ 0.001).
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hypothermia of 32°C from trauma until final imaging. As
expected, hypothermia alone did prove to be strongly
protective, but 1 μM dexmedetomidine was even more
effective at reducing trauma intensity. Interestingly, as
described before in in vivo models of incomplete cerebral
ischemia, a combination of hypothermia and 1 μM dex-
medetomidine did not result in synergistic effects [7].
In a clinical setting, unpredictability is in the nature of
TBI and application of any specific therapy will inevitably
be delayed. Therefore we investigated the effect of dexme-
detomidine when applied 2 or 3 h after trauma. In our
model dexmedetomidine proved to be even more efficient
when application was delayed by 2 h. However, by delay-
ing application for 3 h no appreciable difference could be
observed any more compared to immediate application.
We acknowledge that our results should be inter-
preted within the context of several limitations.
Propidium iodide labels the DNA of any disrupted cell
and we were therefore not able to distinguish between
necrosis and apoptosis. However, we aimed to quantify the
total amount of cell death and it is agreed that propidium
iodide uptake correlates well with the number of damaged
cells [15,25].
We opted for organotypic slice cultures because this
model allows easy access to in vitro manipulation of ner-
vous tissue and yet mimics closely the in vivo state of the
tissue with respect to morphological and functional char-
acteristics [26,27]. Concerning the extrapolation to an in
vivo situation, results from organotypic slice cultures have
been demonstrated to be a satisfying compromise between
dissociated cell culture and in vivo models using whole
animals [28,29]. We admit, however, that extrapolation of
our results to the in vivo situation is complex. In a living
organism, the development and the outcome from TBI is
significantly affected by a plethora of different variables
that can only partly, if at all, be taken into consideration in
an in vitro model (e.g. cerebral perfusion pressure, edema
of surrounding tissue, focal or global cerebral ischemia).
Such conditions may be affected by dexmedetomidine
independently from its direct effects on neuronal survival.
Despite these disadvantages we believe that our model is
appropriate as it focuses on the mechanical component of
the injury and allows the analysis of the intrinsic neuro-
protective properties of a drug independently from its pos-
sible interactions with confounding variables that can only
poorly be controlled in an in vivo setting.
Conclusion
We have found that dexmedetomidine has a protective
effect on hippocampal slice cultures subjected to a focal
mechanical trauma. The maximum effect was observed at
1 μM, with the observed trauma reduction being signifi-
cantly more pronounced than observed in slices treated
with hypothermia. Trauma intensity did not further
decline when applying dexmedetomidine and hypothermia
simultaneously. Also, dexmedetomidine’s effect was par-
tially reversed by simultaneous application of MEK1 Inhi-
bitor PD98059 indicating the involvement of the ERK-
signalling cascade.
Key messages
• Dexmedetomidine exerts a neuroprotective effect
when administered after TBI in this model of organoty-
pic hippocampal slice cultures
• The protective effect of dexmedetomidine is signifi-
cantly stronger than the effect of mild hypothermia at
32°C
• Dexmedetomidine has a protective effect even if
application after TBI is delayed by 2 and 3 h, respectively
• Activation of ERK might be involved in mediating
Dexmedetomidine’s protective effect
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